Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction

American Journal of Cardiology

Volumn 92, Issue 8, 2003, Pages 977-980

  Cutlip, Donald E ^a   Ricciardi, Mark J ^b   Ling, Frederick S ^b   Carrozza Jr , Joseph P ^b   Dua, Vineet ^b   Garringer, Jason ^b   Giri, Satyendra ^b   Caputo, Ronald P ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; EMERGENCY WARD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZATION; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0141594879     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00983-4     Document Type: Article

References (11)

1. Montalescot G., Barragan P., Wittenberg O., Ecollan P., Elhadad S., Villain P., Boulenc J.M., Morice M.C., Maillard L., Pansieri M., Choussat R., Pinton P. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 344:2001;1895-1903.
2. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition the GUSTO V randomised trial . Lancet. 357:2001;1905-1914.
3. Stone G.W., Peterson M.A., Lansky A.J., Dangas G., Mehran R., Leon M.B. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol. 39:2002;591-597.
4. Schroder R., Dissmann R., Bruggemann T., Wegscheider K., Linderer T., Tebbe U., Neuhaus K.L. Extent of early ST segment elevation resolution a simple but strong predictor of outcome in patients with acute myocardial infarction . J Am Coll Cardiol. 24:1994;384-391.
5. van den Merkhof L.F.M., Zijlstra F., Olsson H., Grip L., Veen G., Bar F.W., van den Brand M.J., Simoons M., Verheugt F.W. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty; results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 33:1999;1528-1532.
6. Cutlip D.E., Cove C.J., Irons D., Kalaria V., Le M., Cronmiller H., Caufield L., Pomerantz R.M., Ling F.S. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am J Cardiol. 88:2001;62-64.
7. Gassler J., Topol E. Reperfusion revisited beyond TIMI 3 flow . Clin Cardiol. 22:(suppl 8):1999;IV-20-IV-29.
8. Neumann F., Blasini R., Schmitt C., Alt E., Dirschinger J., Gawaz M., Kastrati A., Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 98:1998;2695-2701.
9. Stone G.W., Grines C.L., Cox D.A., Garcia E., Tcheng J.E., Griffin J.J., Guagliumi G., Stuckey T., Turco M., Carroll J.D., Rutherford B.D., Lansky A.J. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 346:2002;957-966.
10. Jennings L.K., Jacoski M.V., White M.M. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Intervent Cardiol. 15:2002;45-60.
11. Batchelor W.B., Tolleson T.R., Huang Y., Larsen R.L., Mantell R.M., Dillard P., Davidian M., Zhang D., Cantor W.J., Sketch M.H. Jr, et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide . Circulation. 106:2002;1470-1476.